Surrozen, Inc./DE
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
SRZN$32.64+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Collaboration and license revenue | $5,000 | $— |
| Research service revenue – related party | — | 983 |
| Total revenue | 5,000 | 983 |
| Operating expenses: | ||
| Research and development | 9,328 | 6,558 |
| General and administrative | 6,128 | 3,976 |
| Total operating expenses | 15,456 | 10,534 |
| Loss from operations | (10,456) | (9,551) |
| Interest income | 912 | 296 |
| Loss on amendment and cancellation of warrants | — | (2,073) |
| Loss on execution of the 2025 PIPE | — | (71,084) |
| (Loss) gain on change in fair value of tranche liability | (76,855) | 16,340 |
| Gain on settlement of tranche liability | — | 1,117 |
| Other (expense) income, net (Note 3) | (41,106) | 37,985 |
| Net loss and comprehensive loss | $(127,505) | $(26,970) |
| Net loss per share attributable to common stockholders, basic and diluted | $(11.65) | $(7.43) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 10,949 | 3,628 |
Condensed Consolidated Statements of Stockholders’ Deficit
(In thousands)
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common stock · paid-in · Accumulated · stockholders’ | |||||
| Shares | Amount | capital | deficit | deficit | |
| Balance at December 31, 2025 | 9,775 | $1 | $339,522 | $(527,285) | $(187,762) |
| Issuance of common stock under the ATM program | 1,400 | — | 26,858 | — | 26,858 |
| Issuance of common stock upon warrant exercise | 289 | — | 8,065 | — | 8,065 |
| Issuance of common stock upon option exercises | 8 | — | 92 | — | 92 |
| Vesting of restricted stock units | 18 | — | — | — | — |
| Stock-based compensation expense | — | — | 2,105 | — | 2,105 |
| Net loss | — | — | — | (127,505) | (127,505) |
| Balance at March 31, 2026 | 11,490 | $1 | $376,642 | $(654,790) | $(278,147) |
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common stock · paid-in · Accumulated · stockholders’ | |||||
| Shares | Amount | capital | deficit | equity | |
| Balance at December 31, 2024 | 3,262 | $— | $263,879 | $(285,259) | $(21,380) |
| Issuance of common stock in the 2025 PIPE | 5,213 | 1 | 53,189 | — | 53,190 |
| Vesting of restricted stock units | 20 | — | — | — | — |
| Stock-based compensation expense | — | — | 834 | — | 834 |
| Net loss | — | — | — | (26,970) | (26,970) |
| Balance at March 31, 2025 | 8,495 | $1 | $317,902 | $(312,229) | $5,674 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.